Swiss pharma giant Novartis AG NVS reported better-than-expected results for the fourth quarter of 2024. Core earnings (excluding one-time charges) of $1.98 per share easily beat the Zacks Consensus ...

Earnings from continuing operations at Swiss pharmaceutical firm Novartis grew from last year, the firm revealed in results ...